Bin Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bin Peng has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Denghai Zhang
Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, China
3 shared publications - Chunxin Yang
Pharmaceutical Department, Zhong Shan Hospital, Shanghai Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, China.
2 shared publications - Georges Uzan
INSERM UMR-S 1193, Université Paris-Saclay, 94800 Villejuif, France
2 shared publications - Lu Cao
Department of Clinical Laboratory Diagnostics, Postgraduate Education College, Ningxia Medical University, Yinchuan, 750004, China.
2 shared publications Xue Zhang
Shanghai Health Commission Key Lab of Artificial Intelligence-Based Management of Inflammation and Chronic Diseases, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China; School of Basic Medicine, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
2 shared publications- Xue Zhang
Department of Clinical Laboratory Diagnostics, Postgraduate Education College, Ningxia Medical University, Yinchuan, 750004, China.
2 shared publications
Latest Publications
- 16 March 2024
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 22 (3) , 286-294
Ferroptosis inhibitors reduce celastrol toxicity and preserve its insulin sensitizing effects in insulin resistant HepG2 cells
- 16 March 2024
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 22 (3) , 286-294
Ferroptosis inhibitors reduce celastrol toxicity and preserve its insulin sensitizing effects in insulin resistant HepG2 cells
- 18 April 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (10) , 6814-6824
Celastrol reverses palmitic acid (PA)‐caused TLR4‐MD2 activation‐dependent insulin resistance via disrupting MD2‐related cellular binding to PA
Elevated plasma statured fatty acids (FFAs) cause TLR4/MD2 activation‐dependent inflammation and insulin tolerance, which account for the occurrence and development of obesity. It has been confirmed that statured palmitic acid (PA) (the most abundant FFA) could bind MD2 to cause cellular inflammation. The natural compound celastrol could improve obesity, which is suggested via inhibiting inflammation, yet the detailed mechanism for celastrol is still unclear. As celastrol is reported to directly target MD2, we thought disrupting the binding between FFAs and MD2 might be one of the ways for celastrol to inhibit FFAs‐caused inflammation and insulin resistance. In this study, we found evidence to support our hypothesis: celastrol could reverse PA‐caused TLR4/MD2 activation‐dependent insulin resistance, as determined by glucose‐lowering ability, cellular glucose uptake, insulin action‐related proteins and TLR4/MD2/NF‐κB activation. Bioinformatics and cellular experiments showed that both celastrol and PA could bind MD2, and that celastrol could expel PA from cells. Finally, celastrol could reverse high fat diet caused hyperglycemia and obesity, and liver NF‐kB activations. Taking together, we proved that celastrol could reverses PA‐caused TLR4‐MD2 activation‐dependent insulin resistance via disrupting PA binding to MD2.
- 18 April 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (10) , 6814-6824
Celastrol reverses palmitic acid (PA)‐caused TLR4‐MD2 activation‐dependent insulin resistance via disrupting MD2‐related cellular binding to PA
Elevated plasma statured fatty acids (FFAs) cause TLR4/MD2 activation‐dependent inflammation and insulin tolerance, which account for the occurrence and development of obesity. It has been confirmed that statured palmitic acid (PA) (the most abundant FFA) could bind MD2 to cause cellular inflammation. The natural compound celastrol could improve obesity, which is suggested via inhibiting inflammation, yet the detailed mechanism for celastrol is still unclear. As celastrol is reported to directly target MD2, we thought disrupting the binding between FFAs and MD2 might be one of the ways for celastrol to inhibit FFAs‐caused inflammation and insulin resistance. In this study, we found evidence to support our hypothesis: celastrol could reverse PA‐caused TLR4/MD2 activation‐dependent insulin resistance, as determined by glucose‐lowering ability, cellular glucose uptake, insulin action‐related proteins and TLR4/MD2/NF‐κB activation. Bioinformatics and cellular experiments showed that both celastrol and PA could bind MD2, and that celastrol could expel PA from cells. Finally, celastrol could reverse high fat diet caused hyperglycemia and obesity, and liver NF‐kB activations. Taking together, we proved that celastrol could reverses PA‐caused TLR4‐MD2 activation‐dependent insulin resistance via disrupting PA binding to MD2.
- Open Access
- 9 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-11
Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol
Celastrol is a novel anti-tumor agent. Ways to further enhance this effect of celastrol has attracted much research attention. Here, we report that celastrol treatment can elevate miR-223 in human breast cancer cell line MCF-7 and prostate cancer PC3. Down-regulating miR-223 could increase the number of viable cells, yet it further reduced viable cells in samples that were treated by celastrol; up-regulation of miR-223 displayed opposite effects. Celastrol’s miR-223 induction might be due to NF-κB inhibition and transient mTOR activation: these two events occurred prior to miR-223 elevation in celastrol-treated cells. NF-κB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-κB inhibitor or celastrol was reduced by the use of mTOR inhibitor. Finally and interestingly, miR-223 also could affect NF-κB and mTOR and the effects were different between cells treated or not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular viability in the presence of celastrol or not. For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells, and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines. We thus provide a novel way to increase celastrol’s anti-cancer effects.
- 9 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-11
Open AccessInhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol
Celastrol is a novel anti-tumor agent. Ways to further enhance this effect of celastrol has attracted much research attention. Here, we report that celastrol treatment can elevate miR-223 in human breast cancer cell line MCF-7 and prostate cancer PC3. Down-regulating miR-223 could increase the number of viable cells, yet it further reduced viable cells in samples that were treated by celastrol; up-regulation of miR-223 displayed opposite effects. Celastrol’s miR-223 induction might be due to NF-κB inhibition and transient mTOR activation: these two events occurred prior to miR-223 elevation in celastrol-treated cells. NF-κB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-κB inhibitor or celastrol was reduced by the use of mTOR inhibitor. Finally and interestingly, miR-223 also could affect NF-κB and mTOR and the effects were different between cells treated or not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular viability in the presence of celastrol or not. For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells, and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines. We thus provide a novel way to increase celastrol’s anti-cancer effects.
- Open Access
- 4 March 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 146
Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells
Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects. Concurrent use of siRNA to increase celastrol’s anti-tumor effects through HSP70 interference has been reported, but because siRNA technology is difficult to clinically apply, an alternative way to curb unwanted HSP70 elevation caused by celastrol treatment is worth exploring.
- 4 March 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 146
Open AccessPeptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells
Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects. Concurrent use of siRNA to increase celastrol’s anti-tumor effects through HSP70 interference has been reported, but because siRNA technology is difficult to clinically apply, an alternative way to curb unwanted HSP70 elevation caused by celastrol treatment is worth exploring.